Introduction
Infection induces the rapid activation of innate immunity. Innate immune activation serves two purposes, it limits pathogen replication whilst the clonal selection of B and T cells occurs and it favours the development of the appropriate adaptive response [1] .
Current information on the kinetics of innate immune activation stems largely from animal models, yet there is a need to define these processes in humans; such knowledge promises to enhance the efficacy of vaccines and other immunotherapeutic strategies. However, studying the early stages of infection in humans presents both logistical and ethical problems.
Natural killer (NK) cells are important in the innate immune response to infected cells and to tumours [2, 3] . Early animal studies revealed that NK cell activation occurred within two to three days of viral infection [4, 5] and NK cells are known to be critical in antiviral immunity [3, [6] [7] [8] [9] . Activated NK cells destroy infected cells directly and produce cytokines, such as IFN-γ, that favour the development of a cytotoxic T cell response [2, 10] . Rare human NK cell deficiencies are associated with increased susceptibility to viral infection, revealing the importance of human NK cells in antiviral immunity [11, 12] . However, analysing the timeline of human NK cell activation in response to viral infection in vivo remains difficult.
Virus-infected patients show evidence of NK cell activation compared to uninfected controls but whilst vaccination allows controlled studies to be performed, the analysis of pre-infection status and very early post-infection events remains challenging [3, [13] [14] [15] [16] [17] [18] . Hence, our view of the early stages of NK cell activation is largely based on studies performed using model species.
Reovirus, a non-enveloped dsRNA virus, is pathogenic in mice and induces a type I interferon (IFN-I) response [19] . Whilst it is not a significant human pathogen, reovirus has the interesting property of preferentially killing tumour cells leading to its evaluation as a therapeutic agent [20] . The anti-cancer effects of reovirus and other oncolytic viruses appear to be linked to a two-fold mode of action, namely the direct killing of tumour cells and the induction of innate and adaptive anti-tumour immunity [21] [22] [23] [24] . Intravenous delivery of reovirus into patients is associated with its rapid loss from the circulation; in eight out of ten treated patients, the virus was undetectable in the bloodstream after one hour post-infection [25] . Despite the presence of neutralising antibodies, reovirus reached the tumour and was associated with tumour cell apoptosis [25] . This same trial allowed us to study infection-induced human NK cell activation under controlled conditions. Our results define the kinetics of human NK cell activation in response to viral infection in vivo.
Materials and methods

Ethical approval and the clinical trial
This study was undertaken following institutional and national ethical and regulatory approval. Patients were enrolled in the trial and provided blood samples following informed consent. The patient group and the trial are described elsewhere [25] .
Antibodies
The following antibodies were used in this study; CD69 (clone FN50); CD56 (clone 
Flow cytometry and gene expression analysis
Cell surface expression of CD69 and tetherin was determined using flow cytometry on either purified NK cells (P1-P4) or by gating on CD56+CD3 neg NK cells in Peripheral Blood Mononuclear Cells (PBMC; P5-P10). NK cells were purified by indirect magnetic immunoselection (Miltenyi Biotech). Flow cytometry was performed using a Becton Dickinson (BD) LSRII or BD FACSCalibur flow cytometer using BD FACSDiva software and BD CellQuest Pro software, respectively. For gene expression studies, mRNA was converted to cDNA (using random hexamer priming) and expression of IFIT1, IFI44L, 18S RNA or ABL1 was analysed by quantitative (q)RT-PCR using Taqman reagents from Applied Biosystems. Data was normalised to either 18S RNA or ABL1 mRNA (as indicated) and the fold-change induced during infection calculated using the ΔΔCt method.
In vitro studies
PBMCs from healthy donors were co-incubated with reovirus (REOLYSIN¨;
Oncolytics Biotech Inc.) at a multiplicity of infection (MOI) of 0.2-1 in the presence of either the anti-human IFN-I antibody cocktail or matched serum/IgG controls.
Degranulation assays were performed forty-eight hours post-infection using the K562 target cell line in the presence of GolgiStop (from BD Biosciences) and the antiCD107a antibody [26] . For analysis of isolated NK cells and fractionation of PBMC, the NK cells were purified using indirect magnetic immunoselection reagents (Miltenyi Biotec) and the NK cell depleted PBMC (PBMCΔNK) were eluted from the column.
Results
Ten patients (P1-10; aged 50-74) with colorectal cancer liver metastases were enrolled in a clinical endpoint trial to assess the delivery of reovirus to the metastatic tumour [25] . Each patient received between one and five intravenous infusions of 10 10 units of reovirus prior to planned surgical resection of their tumour. Seven of the ten patients received reovirus daily for five days, P7 received four doses, P8 a single dose and P1 received three doses with an altered timing (Fig. 1a) . Six of the ten patients experienced fever and several experienced flu-like symptoms during treatment, consistent with viral infection [25] .
Blood samples taken before and during treatment were used to analyse the NK cell phenotype. Infection induced rapid expression of the lymphocyte activation marker CD69 on the NK cells, peaking forty-eight hours post-infection (Fig. 1b, c) .
A single dose of reovirus was sufficient to induce this activation, as shown in P8 who received just one dose and in P1, in whom more than 60% of peripheral blood NK cells were CD69+ before the second dose was administered (Fig. 1b) . With the exception of P1 and P8, all patients received two doses of virus before the forty-eight hour sample (when NK cell activation peaked) and a further two doses between the forty-eight hour and ninety-six hour samples (Fig. 1a) . However, NK cell activation declined after forty-eight hours in all patients, suggesting that NK cells were refractory to further stimulation within this period.
Reovirus dsRNA, and indeed other viral nucleic acids, induce type I interferon (IFN-I) responses in animals via pathogen-associated molecular pattern receptor recognition. The cytoplasmic RNA sensor RIG-I recognises the 5Õ-diphosphate present on reovirus dsRNA and induces IFN gene expression [27] . It is long established that IFN treatment activates human NK cells in vivo [19, [28] [29] [30] . We then performed experiments to analyse the response to reovirus in vitro.
We treated PBMC with reovirus in the presence or absence of antibodies that block the IFN-I response. Treated PBMC were then co-cultured with tumour target cells and the tumour-mediated degranulation of the NK cells in the PBMC analysed using flow cytometry [26] . This demonstrated that reovirus treatment of PBMC resulted in the IFN-I dependent, functional activation of the NK cells ( Fig. 3a) , consistent with previously published data [23] . We then treated PBMC with reovirus for forty-eight have revealed that NK cell activity persists beyond this initial wave of activation [14, [35] [36] [37] . Interestingly, we found a significant increase in the absolute numbers of NK cells in the pre-surgery samples; in two patients (P9 and P7) we detected a six-fold and a thirteen-fold increase respectively (Fig. 4) . Expression of KIR molecules is clonal and maintained following cell division and KIRs thus provide markers for analysis of putative clonal expansions. Cell surface expression of CD158a, CD158b
and CD158e antigens identified eight distinct populations constituting between ~2% through to ~50% of total NK cells (Supplementary Table 1 ). However, we did not detect clonal expansions that could account for the changes in absolute numbers seen between the ninety-six hour and pre-surgery samples; this suggests that the increase in the absolute numbers of NK cells was due to polyclonal expansion.
Discussion
The showed that a strong response could be detected within twenty-four hours of treatment. The results suggest that the initial IFN-I response (and NK cell activation) was followed by a refractory period during which the patients were unable to respond to further exposure to reovirus. Most adults have been exposed to reovirus and all patients in the trial had neutralising antibodies that increased in titre around days 3-5 post-infection [25] . Whether this boost in antibody titre blocks the IFN-I response to subsequent doses of reovirus seems unlikely, but nevertheless remains unclear. An intriguing alternative is that the refractory period is related to that observed in mouse viral infection models [50, 51] ; the initial viral infection induces an IFN response which is followed by a refractory period in which further IFN responses to unrelated pathogens are blunted. This refractory period has been suggested to contribute to the enhanced susceptibility to unrelated, secondary infections that can follow viral infection. In mice, the mechanisms underlying this refractory period include a reduced capacity of plasmacytoid dendritic cells (pDC) to produce IFN [51] and the induction of OASL1, a negative regulator of IFN production [52] . However, other homeostatic control mechanisms that halt responses, including molecules that target IFN production and downstream signalling pathways, may also influence responses [53] [54] [55] [56] [57] . Interestingly, tetherin was proposed to act as a feedback inhibitor of IFN production by engaging the receptor ILT7 on pDC [58] . However, whilst ILT7
ligation was confirmed to halt IFN production, a role for tetherin in this process was subsequently called into question [59] . To the best of our knowledge, the data presented here is the first demonstration of this refractory period in humans. However, the constraints of working within a clinical trial make these conclusions speculative. phenotyping where approximately 50% of NK cells lack KIR expression [60] .
However, we did not analyse expression of NKG2C expressing cells; this population expands in both cytomegalovirus and hantavirus infection and for the latter, expanded cells expressed at least one KIR molecule against a self-MHC class I molecule, indicating that the expanded NK cells were functionally licensed [14, 61] . The KIR and MHC haplotype of the patients within our study was unavailable to us and we do not know whether the expansions we detected were confined to licensed populations.
The significance of this relatively late post-infection phenotype is unclear. There is emerging data that suggest a role for NK cells beyond the immediate post-infection stage [14] . The significance of these more durable NK cell responses, for example whether they represent the formation of a memory-like NK cell population [35] , or a role for NK cells in the cessation of T cell responses currently remains unclear [36, 37] .
The ability of reovirus to induce NK cell activation is likely to contribute to its oncolytic activity in vivo. However, effective oncolytic virus treatment will depend upon achieving the correct balance of antiviral and anti-tumour activity [20, 62] . For example, depletion of NK cells limits the efficacy of both vesicular stomatitis virus and reovirus virus treatment, consistent with stimulation of the anti-tumour effector function of this population [63, 64] . However, the antiviral activity of NK cells has been shown to impede the action of oncolytic herpes simplex virus against glioblastoma [65] . In the patients treated here, replication competent reovirus was recovered from the colorectal liver metastases but not from surrounding healthy tissue, suggesting effective targeting of the virus to the tumour [25] . Furthermore, ex vivo studies show that reovirus activates NK cells from the liver and enhances their cytotoxic activity towards colorectal cancer cell lines [23] . However, viral infection in the liver can induce potent immunosuppressive activity (via IL-10 and TGF-β) that limits NK cell production of IFN-γ; similar effects would be expected to blunt oncolytic virus induced NK cell activation and anti-tumour immunity [66] .
In summary, use of a therapeutic virus in a clinical trial has enabled us to study the kinetics of NK cell activation in response to viral infection. The increasing use of therapeutic viruses promises to provide new opportunities to study the activation and resolution of the human immune response in vivo and provide key information that is currently inferred from studies performed in other species.
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We NK cells from P7-10 were analysed for expression of CD158a, b and e at ninety-six hours post-infection and in the pre-surgery sample (Sgy). The fold change in absolute numbers of NK cells between these two samples is shown next to the patient number (e.g. for P7, ~13X). The values indicate the size of the respective populations as a percentage of the total CD56+CD3 neg NK cells. The three markers identify eight distinct populations listed in the left hand column. Expressed CD158 molecules are denoted by upper case letters (e.g. ABC is CD158a+, b+, c+) or lower case for non-expressed (abc denotes the triple negative population of CD158a neg , b neg , c neg ). !
